Gut bacteria may tame chemo inflammation in breast cancer
NCT ID NCT07607548
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether taking a daily probiotic supplement could reduce inflammation caused by chemotherapy or immunotherapy in women with breast cancer. Sixty women took either a probiotic or a placebo for eight weeks while receiving treatment. Researchers measured changes in blood markers of inflammation to see if the probiotic helped.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Probiotic (Lactiplantibacillus plantarum 299v)
- What this could lead to
- If it works, this could point toward a simple way to reduce harmful inflammation during breast cancer treatment, potentially improving outcomes.
- What could go wrong
- This is a small, early-stage study focused on blood markers, not on whether cancer comes back. The results may not lead to a proven treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
60 people
The number who actually took part.
- Started
-
Oct 2022
- Finished
-
Apr 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * first-time chemotherapy * written consent to participate in the research * no antibiotic and probiotic therapy in the last 3 months Exclusion Criteria: * serious comorbidities (chronic renal failure, diabetes, autoimmune diseasese, unstable coronary artery disease or other cancers) * previous history of cancer * smoking cigarettes or using other stimulants * another probiotic supplementation * qualification for another type of treatment - surgery or hormone therapy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Greater Poland Cancer Centre
Poznan, 61-866, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?
- Tiny magnetic seeds could guide surgeons to the right lymph node
- New PET tracer aims to light up hidden cancer targets
- Gut bacteria supplement tested against chemo hair loss
- Can a mindfulness program boost Self-Compassion in breast cancer survivors?
- Can a Decades-Old Anti-Inflammatory drug quiet the joint pain that drives women off breast cancer therapy?